Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 73,981	$ 50,708
Marketable securities	22,518	106,513
Research and development tax credit receivable	2,248	2,443
Prepaid expenses and other current assets	2,096	32,826
Total current assets	100,843	192,490
Property and equipment, net	839	285
Operating lease right-of-use assets	1,713	2,652
Goodwill	16,836	16,836
Research and development tax credit receivable	1,232	1,225
Other non-current assets	11,322	33,777
Total assets	132,785	247,265
Current liabilities:
Current portion of long-term debt	37,668	0
Current portion of operating lease liability	960	900
Accounts payable	7,890	7,679
Accrued expenses	7,334	7,151
Other current liabilities	1,941	5,270
Total current liabilities	55,793	21,000
Long-term debt	91,614	142,397
Long-term operating lease liability	780	1,707
Other non-current liabilities	5,743	3,917
Total liabilities	153,930	169,021
Shareholders’ (deficit) equity:
Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; 488 issued and outstanding at December 31, 2022 and 2021, respectively	5	5
Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 62,878 and 58,620 issued and outstanding at December 31, 2022 and 2021, respectively	628	586
Additional paid-in capital	589,783	549,349
Accumulated deficit	(585,220)	(447,756)
Accumulated other comprehensive loss	(26,341)	(23,940)
Total shareholders’ (deficit) equity	(21,145)	78,244
Total liabilities and shareholders’ (deficit) equity	$ 132,785	$ 247,265